<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33962678</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-6606</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>07</Day></PubDate></JournalIssue><Title>Molecular brain</Title><ISOAbbreviation>Mol Brain</ISOAbbreviation></Journal><ArticleTitle>Repeated infusion of mesenchymal stem cells maintain the condition to inhibit deteriorated motor function, leading to an extended lifespan in the SOD1G93A rat model of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>76</StartPage><MedlinePgn>76</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">76</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13041-021-00787-6</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative fatal disorder in which motor neurons within the brain and spinal cord degenerate. A single infusion of mesenchymal stem cells (MSCs) delays disease progression by protecting motor neurons and restoring the blood-spinal cord barrier in the SOD1G93A transgenic ALS rat model. However, the therapeutic effect of a single infusion of MSCs is transient and does not block disease progression. In this study, we demonstrated that repeated administration of MSCs (weekly, four times) increased the survival period, protected motor functions, and reduced deterioration of locomotor activity compared to a single infusion and vehicle infusion, after which rats displayed progressive deterioration of hind limb function. We also compared the days until gait ability was lost in rats and found that the repeated-infused group maintained gait ability compared to the single-infusion and vehicle-infusion groups. These results suggest that repeated administration of MSCs may prevent the deterioration of motor function and extend the lifespan in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Magota</LastName><ForeName>Hirotoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, 060-8556, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tominaga Hospital, Naniwa-ku, Osaka-shi, Osaka, 556-0017, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Masanori</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7961-9698</Identifier><AffiliationInfo><Affiliation>Department of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, 060-8556, Japan. msasaki@sapmed.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Yale University School of Medicine, New Haven, CT, 06510, USA. msasaki@sapmed.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuroscience and Regeneration Research, VA Connecticut Healthcare System, West Haven, CT, 06516, USA. msasaki@sapmed.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kataoka-Sasaki</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, 060-8556, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oka</LastName><ForeName>Shinichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, 060-8556, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ukai</LastName><ForeName>Ryo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, 060-8556, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiyose</LastName><ForeName>Ryo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, 060-8556, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tominaga Hospital, Naniwa-ku, Osaka-shi, Osaka, 556-0017, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onodera</LastName><ForeName>Rie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, 060-8556, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kocsis</LastName><ForeName>Jeffery D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale University School of Medicine, New Haven, CT, 06510, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuroscience and Regeneration Research, VA Connecticut Healthcare System, West Haven, CT, 06516, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honmou</LastName><ForeName>Osamu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, 060-8556, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Yale University School of Medicine, New Haven, CT, 06510, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuroscience and Regeneration Research, VA Connecticut Healthcare System, West Haven, CT, 06516, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Brain</MedlineTA><NlmUniqueID>101468876</NlmUniqueID><ISSNLinking>1756-6606</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="Y">Longevity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="N">Mesenchymal Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055647" MajorTopicYN="N">Rats, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Mesenchymal stem cells intravenous</Keyword><Keyword MajorTopicYN="N">Multiple doses</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33962678</ArticleId><ArticleId IdType="pmc">PMC8103621</ArticleId><ArticleId IdType="doi">10.1186/s13041-021-00787-6</ArticleId><ArticleId IdType="pii">10.1186/s13041-021-00787-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet (London, England) 2011;377(9769):942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki K, Ohta Y, Nagai M, Morimoto N, Kurata T, Takehisa Y, et al. Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J Neurosci Res. 2011;89(5):718&#x2013;728. doi: 10.1002/jnr.22594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22594</ArticleId><ArticleId IdType="pubmed">21337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S. Alterations of the blood-spinal cord barrier in sporadic amyotrophic lateral sclerosis. Neuropathology. 2015;35(6):518&#x2013;528. doi: 10.1111/neup.12221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12221</ArticleId><ArticleId IdType="pubmed">26242689</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Saporta S, Haller E, Kolomey I, Bennett SP, Potter H, et al. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS ONE. 2007;2(11):e1205. doi: 10.1371/journal.pone.0001205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001205</ArticleId><ArticleId IdType="pmc">PMC2075163</ArticleId><ArticleId IdType="pubmed">18030339</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Haller E, Saporta S, Kolomey I, Nicosia SV, Sanberg PR. Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res. 2007;1157:126&#x2013;137. doi: 10.1016/j.brainres.2007.04.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.04.044</ArticleId><ArticleId IdType="pubmed">17512910</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sengillo JD, Sagare AP, Zhao Z, Ma Q, Zuniga E, et al. Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci U S A. 2014;111(11):E1035&#x2013;E1042. doi: 10.1073/pnas.1401595111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1401595111</ArticleId><ArticleId IdType="pmc">PMC3964055</ArticleId><ArticleId IdType="pubmed">24591593</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, Deane R, Ali Z, Parisi M, Shapovalov Y, O'Banion MK, et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci. 2008;11(4):420&#x2013;422. doi: 10.1038/nn2073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2073</ArticleId><ArticleId IdType="pmc">PMC2895310</ArticleId><ArticleId IdType="pubmed">18344992</ArticleId></ArticleIdList></Reference><Reference><Citation>Magota H, Sasaki M, Kataoka-Sasaki Y, Oka S, Ukai R, Kiyose R, et al. Intravenous infusion of mesenchymal stem cells delays disease progression in the SOD1G93A transgenic amyotrophic lateral sclerosis rat model. Brain Res. 2021 doi: 10.1016/j.brainres.2021.147296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2021.147296</ArticleId><ArticleId IdType="pubmed">33516815</ArticleId></ArticleIdList></Reference><Reference><Citation>Namioka T, Namioka A, Sasaki M, Kataoka-Sasaki Y, Oka S, Nakazaki M, et al. Intravenous infusion of mesenchymal stem cells promotes functional recovery in a rat model of chronic cerebral infarction. J Neurosurg. 2018;1&#x2013;8. 10.3171/2018.5.JNS18140.</Citation><ArticleIdList><ArticleId IdType="pubmed">30485210</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu K, Honmou O, Suzuki J, Houkin K, Hamada H, Kocsis JD. Therapeutic time window of mesenchymal stem cells derived from bone marrow after cerebral ischemia. Brain Res. 2010;1334:84&#x2013;92. doi: 10.1016/j.brainres.2010.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2010.04.006</ArticleId><ArticleId IdType="pubmed">20382136</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita T, Sasaki M, Kataoka-Sasaki Y, Nakazaki M, Nagahama H, Oka S, et al. Intravenous infusion of mesenchymal stem cells promotes functional recovery in a model of chronic spinal cord injury. Neuroscience. 2016;335:221&#x2013;231. doi: 10.1016/j.neuroscience.2016.08.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2016.08.037</ArticleId><ArticleId IdType="pubmed">27586052</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazaki M, Sasaki M, Kataoka-Sasaki Y, Oka S, Suzuki J, Sasaki Y, et al. Intravenous infusion of mesenchymal stem cells improves impaired cognitive function in a cerebral small vessel disease model. Neuroscience. 2019;408:361&#x2013;377. doi: 10.1016/j.neuroscience.2019.04.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2019.04.018</ArticleId><ArticleId IdType="pubmed">30999031</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma. 1995;12(1):1&#x2013;21. doi: 10.1089/neu.1995.12.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.1995.12.1</ArticleId><ArticleId IdType="pubmed">7783230</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M, McHugh J, Tork C, Shelley B, Klein SM, Aebischer P, et al. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS ONE. 2007;2(8):e689. doi: 10.1371/journal.pone.0000689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0000689</ArticleId><ArticleId IdType="pmc">PMC1925150</ArticleId><ArticleId IdType="pubmed">17668067</ArticleId></ArticleIdList></Reference><Reference><Citation>Honmou O, Yamashita T, Morita T, Oshigiri T, Hirota R, Iyama S, et al. Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series. Clin Neurol Neurosurg. 2021;203:106565. 10.1016/j.clineuro.2021.106565.</Citation><ArticleIdList><ArticleId IdType="pubmed">33667953</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>